NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 229
(Total Views: 378)
Posted On: 09/08/2021 4:42:36 PM
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Slated for Live Webcast at VirtualInvestorConferences.com
InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), will be featured at the upcoming VirtualInvestorConferences.com. InMed president and CEO is scheduled to present a real-time, interactive presentations during the two-day conference; InMed’s presentation will start at 1:30 p.m. ET on Sept. 8, 2021. During the presentation Adams will provide an overview of the company’s recent highlights as well as answer questions from potential investors in real time. Company highlights include the announcement that it has increased the yield of its proprietary IntegraSyn(TM) rare cannabinoid manufacturing approach to 5 g/L, further improving the overall economics in advance of commercial-scale production and that it has signed a nonbinding letter of intent to acquire BayMedica, a private company that specializes in the manufacture and commercialization of rare cannabinoids. In addition, as part of a phase 2 clinical trial, InMed has filed clinical trial applications in several countries. Virtual Investor Conferences (“VIC”) has developed a reputation for being a leading proprietary investor conference series; VIC events provide an interactive forum for publicly traded companies to meet and present directly with investors.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), will be featured at the upcoming VirtualInvestorConferences.com. InMed president and CEO is scheduled to present a real-time, interactive presentations during the two-day conference; InMed’s presentation will start at 1:30 p.m. ET on Sept. 8, 2021. During the presentation Adams will provide an overview of the company’s recent highlights as well as answer questions from potential investors in real time. Company highlights include the announcement that it has increased the yield of its proprietary IntegraSyn(TM) rare cannabinoid manufacturing approach to 5 g/L, further improving the overall economics in advance of commercial-scale production and that it has signed a nonbinding letter of intent to acquire BayMedica, a private company that specializes in the manufacture and commercialization of rare cannabinoids. In addition, as part of a phase 2 clinical trial, InMed has filed clinical trial applications in several countries. Virtual Investor Conferences (“VIC”) has developed a reputation for being a leading proprietary investor conference series; VIC events provide an interactive forum for publicly traded companies to meet and present directly with investors.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)